Molecular Remissions With Anti-Cd22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated With Improved Complete Remission Durations During Phase I And Iii TestingEvgeny Arons,Daniel Gorelik,Maryalice Stetler-Stevenson,Constance M. Yuan,Mark Sokolsky,Hong Zhou,Nai Shun (Nancy) Yao,Shannon Marshall,Katherine Potocka,Erin Fykes,Ira Pastan,Robert J. KreitmanBLOOD(2018)引用 1|浏览4暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要